Dr Holger Auner is Clinical Reader in Molecular Haemato-oncology at Imperial College London. He received his MD from Karl-Franzens University Graz, Austria, where he also trained in Internal Medicine/Haematology-Oncology and studied genetic instability in myeloid leukaemias in the laboratory of Professor Heinz Sill. He was awarded a Kay Kendall Leukaemia Fund Junior Research Fellowship  to join the group of Professor Niall Dillon at the MRC Clinical Sciences Centre in London and obtained his PhD for work on plasma cell biology from Imperial College London. He was the recipient of a Cancer Research UK (CRUK) Clinician Scientist Fellowship in 2012, enabling him to establishe a research group in the Centre for Haematology at Imperial College London. Currently, he holds a CRUK Advanced Clinician Scientist Fellowship, is Head of Translational Research at Imperial's Hugh and Josseline Langmuir Centre for Myeloma Research and is an Honorary Consultant in Haematology (Imperial College Healthcare NHS Trust). Dr Auner’s primary research interest is to better understand the molecular mechanisms that coordinate protein degradation pathways with cellular metabolism in multiple myeloma and other cancers. His lab also investigates how proteomic and metabolic homeostasis depend on tissue physical properties and vice versa, using time-resolved omics approaches in a range of cross-disciplinary collaborations with academic and pharmaceutical industry partners. Dr Auner is board member of the UK Myeloma Research Alliance (UKMRA), member of the European Myeloma Network (EMN), and principal/chief investigator of national and international phase 1 to 3 trials.

Dr Holger W Auner has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Apollo Therapeutics, Janssen, Karyopharm and Takeda.